ArticleCirculation reports2026
Prognostic Stratification Based on Left Ventricular Diastolic Dysfunction and Coronary Microvascular Dysfunction in Patients Without Functional Coronary Artery Stenosis.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The left atrial volume index (LAVi) is a sensitive surrogate marker for left ventricular diastolic dysfunction (LVDD) and is associated with poor outcomes. Although LVDD is associated with coronary microvascular dysfunction (CMD), the prognostic significance of coexisting elevated LAVi and CMD remains unclear. This study aimed to assess the significance of coexisting elevated LAVi and CMD. Methods and Results: We studied 330 patients who underwent intracoronary physiological assessment for suspected ischemia with non-obstructive coronary artery disease. Among these patients, 75 had LVDD, and 107 had coronary flow reserve (CFR) <2.5. Patients were classified into 4 groups: Group 1, normal LAVi and CFR; Group 2, elevated LAVi only; Group 3, impaired CFR only; and Group 4, abnormal LAVi and CFR. The primary endpoints were major adverse cardiovascular events (MACE), including cardiovascular death, acute coronary syndrome, and heart failure requiring hospitalization. During a median follow-up of 759 days, 16 (4.8%) patients experienced 18 events. Event-free survival was significantly lower in Group 4 than in the other groups (P<0.01). Conclusions: The coexistence of elevated LAVi and impaired CFR is associated with a significantly higher risk of MACE. The combination of LAVi and CFR may improve risk stratification in patients without epicardial coronary stenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.